

BEST AVAILABLE COPY

Appl. No. 10/007,459

Amdt. dated May 15, 2006

Reply to Office action of February 22, 2006

AMENDMENTS TO THE CLAIMS

In the claims, please amend claims 11 and 13 as follows:

11. (currently amended) A process for inhibiting expression of a gene in delivering an siRNA into a cell in a target tissue in a mammal, comprising:
- a) mixing the siRNA a double strand RNA oligonucleotide consisting of a sequence that is substantially complementary a portion of a sequence of the gene and a compound selected from the group consisting of amphipathic compounds, polymers and non-viral vectors to form a complex wherein the zeta potential of the complex is less negative than the zeta potential of the siRNA double strand RNA oligonucleotide alone;
 - b) inserting the complex into an efferent or afferent mammalian vessel of the target tissue in vivo thereby increasing permeability of vessels within the target tissue; ~~and, e)~~ and delivering the siRNA double strand RNA oligonucleotide to the cell, wherein the double strand RNA oligonucleotide inhibits expression of the gene.
12. (canceled)
13. (currently amended) The process of claim [[12]] 11 wherein increasing the permeability of the vessel consists of increasing pressure against vessel walls.
14. (original) The process of claim 13 wherein the cell is selected from the group consisting of liver cells, spleen cells, heart cells, kidney cells, prostate cells, skin cells, testis cells, skeletal muscle cells, fat, bladder cells, brain cells, pancreas cells, thymus cells, and lung cells.
15. (previously presented) The process of claim 11 wherein the complex has a positive charge.
16. (previously presented) The process of claim 11 wherein the complex has a negative charge.
17. (previously presented) The process of claim 13 wherein increasing the pressure consists of increasing volume of fluid within the vessel.
18. (previously presented) The process of claim 17 wherein the solution is inserted within 2 minutes.